Esperion Therapeutics Business Summary

Esperion Therapeutics, Inc. (ESPR) is a commercial-stage pharmaceutical company focused on the development and commercialization of non-statin, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. The company generates revenue through two primary streams: U.S. Net Product Revenue, derived from sales of its flagship ACL-inhibitor therapies NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe), and Collaboration Revenue, which includes royalties and milestone payments from international partners such as Daiichi Sankyo Europe and Otsuka Pharmaceutical. As of March 2026, Esperion has expanded its portfolio through the acquisition of Corstasis Therapeutics, adding the FDA-approved nasal spray Enbumyst (bumetanide) to its cardiovascular franchise. The company competes directly with large-cap biopharmaceutical firms like Amgen (Repatha), Regeneron/Sanofi (Praluent), and MannKind (Furoscix), positioning itself as a high-growth, specialized alternative offering oral, once-daily treatments that bridge the gap between statins and injectable biologics. Originally founded by Dr. Roger Newton, a co-developer of Lipitor, Esperion is currently led by President and CEO Sheldon Koenig, who brings over 30 years of cardiovascular leadership from Portola Pharmaceuticals, Sanofi, and Merck. The executive team includes Glenn Brame as Chief Technical Operations Officer, Ben Halladay as Chief Financial Officer, and John Harlow, who was appointed Chief Commercial Officer in late 2025 to drive the company’s "Vision 2040" strategy. The Board of Directors is chaired by J. Martin Carroll, former CEO of Boehringer Ingelheim, and includes notable industry veterans such as Robert E. Hoffman (formerly of Arena Pharmaceuticals) and Craig Thompson (CEO of Cerevance). The company is supported by institutional investors and strategic royalty partners, including Athyrium Capital Management and HealthCare Royalty, which recently provided financing for the Corstasis acquisition.